NCT01753076 - Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis | Biotech Hunter

Enrollment

304

Participants

Timeline

Start Date

December 20, 2012

Primary Completion Date

January 22, 2015

Study Completion Date

January 22, 2015

Conditions

Amyotrophic Lateral Sclerosis

Interventions

DRUG

Ozanezumab

Ozanezumab injection solution

DRUG

Placebo

Normal saline (0.9% sodium chloride) infusion

Trial Locations (35)

2031

GSK Investigational Site, Randwick

3000

GSK Investigational Site, Leuven

4029

GSK Investigational Site, Herston

10126

GSK Investigational Site, Turin

13210

GSK Investigational Site, Syracuse

13353

GSK Investigational Site, Berlin

30625

GSK Investigational Site, Hanover

34295

GSK Investigational Site, Montpellier

37134

GSK Investigational Site, Verona

43210

GSK Investigational Site, Columbus

44789

GSK Investigational Site, Bochum

49503

GSK Investigational Site, Grand Rapids

59037

GSK Investigational Site, Lille

75651

GSK Investigational Site, Paris

81675

GSK Investigational Site, Munich

87042

GSK Investigational Site, Limoges

89081

GSK Investigational Site, Ulm

02114

GSK Investigational Site, Boston

T3M 1M4

GSK Investigational Site, Calgary

N6A 5A5

GSK Investigational Site, London

M4N 3M5

GSK Investigational Site, Toronto

H2L 4M1

GSK Investigational Site, Montreal

H3A 2B4

GSK Investigational Site, Montreal

06202

GSK Investigational Site, Nice

07747

GSK Investigational Site, Jena

252-0380

GSK Investigational Site, Kanagawa

980-8574

GSK Investigational Site, Miyagi

560-8552

GSK Investigational Site, Osaka

3584 CX

GSK Investigational Site, Utrecht

110-744

GSK Investigational Site, Seoul

133-792

GSK Investigational Site, Seoul

136-705

GSK Investigational Site, Seoul

PR2 9HT

GSK Investigational Site, Preston

BN2 5BE

GSK Investigational Site, Brighton

B15 2TT

GSK Investigational Site, Edgbaston